Prof Oliver Grimm speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the results of the phase III NIMBUS trial looking at BCG dosing for bladder cancer.

He explains that the aim was to show that a reduced dosing schedule would be non-inferior to the standard schedule, however the experimental arm was found to be inferior to the standard frequency arm.

Prof Grimm states that we should therefore continue using the standard frequency as recommended but that they did make some interesting findings concerning recurrence in the standard frequency arm which can be attributed to the routine use of repeated TUR prior to BCG induction.